28 results on '"Came, Neil"'
Search Results
2. Immunophenotypic characterisation of acute myeloid leukaemia with UBTF tandem duplications
3. Issue highlights—April 2024
4. Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months
5. Evaluation of T‐cell clonality by anti‐TRBC1 antibody‐based flow cytometry and correlation with T‐cell receptor sequencing.
6. Computational flow cytometry provides accurate assessment of measurable residual disease in chronic lymphocytic leukaemia
7. Computational Flow Cytometry Provides Accurate and Sensitive Measurable Residual Disease Assessment in Chronic Lymphocytic Leukemia
8. Is CD20 positive plasma cell myeloma a unique clinicopathological entity? A study of 40 cases and review of the literature
9. Unsupervised computational detection of measurable residual disease in chronic lymphocytic leukaemia
10. Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: An international harmonized approach for data analysis
11. T-cell clones of uncertain significance in the era of increasingly sensitive flow-cytometry detection
12. The denominator variable in the quantitation of MRD in acute myeloid leukemia
13. An atypical presentation of persistent polyclonal B-lymphocytosis with symptomatic splenomegaly and response to rituximab
14. Bone-marrow plasma cell burden correlates with IgM paraprotein concentration in Waldenström macroglobulinaemia
15. Validation of a modified pre‐lysis sample preparation technique for flow cytometric minimal residual disease assessment in multiple myeloma, chronic lymphocytic leukemia, and B‐non Hodgkin lymphoma
16. A synonymous GATA2 variant underlying familial myeloid malignancy with striking intrafamilial phenotypic variability
17. Haematology Reference Ranges For The Elderly Derived From A Patient Population.: 801
18. Quality of bone marrow iron assessment
19. Should we be routinely testing for circulating clonal plasma cells in patients with multiple myeloma?
20. CD19 Negative Relapse in B-ALL Treated with Blinatumomab Therapy: Avoiding the Trap
21. Aggressive and extramedullary plasma cell myeloma evade bone marrow flow cytometric minimal residual disease detection
22. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting
23. Development, validation and implementation of 8-colour plasma cell flow cytometry at peter maccallum cancer centre
24. Plerixafor Plus Single-Dose Pegfilgrastim for Hematopoietic Stem and Progenitor Cell Mobilization: An Efficient and Safe Regimen In Good and Poor Mobilizer Patients
25. Lessons Learned From an Unusual Presentation of CD3+, CD56− T-Cell Large Granular Lymphocyte Leukemia
26. Utility of Flow Cytometry (FC) in the Assessment of Therapeutic Efficacy in Myelodysplastic Syndromes (MDS) After Therapeutic Intervention.
27. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.
28. Aggressive and extramedullary plasma cell myeloma evade bone marrow flow cytometric minimal residual disease detection.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.